Private Market View

RECORNEA

Trieste, Italy · Founded 2019 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
$4.6M
Last round

Key facts

  • It has raised $4.6M; the latest was Later Stage VC ($15.0M) in Nov 2024.
  • Notable investors include MedTech Innovator, Entrepreneurs First, European Commission, B Heroes, Caique Holding12 tracked in total.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 12 names
  • ·Watchlist + deal alerts for RECORNEA
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for RECORNEA are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About RECORNEA

Developer of a corneal medical device designed to restore the physiological curvature of the cornea with clear and predictable clinical outcomes. The company's device utilizes an implantable medical technology capable of improving the vision of patients suffering from keratoconus, enabling healthcare professionals to treat their patients with various pathological conditions that cause deformation of the cornea.

Sector
Healthcare
HQ
Trieste, Italy
Founded
2019
Employees
6
Ownership
Privately Held (backing)
PA Mark — not yet priced

RECORNEA doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in RECORNEA shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on RECORNEA in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.